Traders should be cautious of this offering as a significant dilutive event. The stock price is likely to face downward pressure, especially if the company begins active sales under the ATM program. Monitor for any announcements of sales volume and pricing, as well as insider trading activity, which could signal management's confidence level.
Price Chart
Executive Summary
iBio, Inc. (IBIO) has filed an S-3 shelf registration statement with the SEC, authorizing the potential sale of up to $200 million in securities, including common stock, preferred stock, debt securities, warrants, and units. A significant portion of this, up to $100 million, is designated for an 'at-the-market' (ATM) offering of common stock through Jefferies LLC. This filing signals the company's intent to raise capital opportunistically, likely to fund its preclinical drug development programs in the obesity and cardiometabolic space.
Key Financial Metrics
Key Facts
- iBio has filed an S-3 shelf registration for up to $200 million in securities.
- Up to $100 million of the offering is for common stock via an 'at-the-market' (ATM) program with Jefferies.
- The company is preclinical-stage with no revenue-generating products, relying on capital raises for operations.
- The market cap is $106 million, meaning the offering could result in massive dilution (up to 75% of shares outstanding).
- The company has a history of significant losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern.
Financial Impact
The offering could raise up to $100 million, representing a 94% increase to its current $106 million market cap. This would result in massive dilution for existing shareholders.
Risk Factors
- Massive shareholder dilution from the potential issuance of new shares.
- Downward pressure on the stock price as new shares are sold into the market.
- The company's preclinical status and lack of revenue create a high risk of failure for its drug candidates.
- The company may need to raise more capital in the future, leading to further dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-021610 |
| Document: tm267370d1_ex4-3.htm | 0001104659-26-021610 |
| CONTEXT: 10-Q (2026-02-10) | 0001420720-26-000004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 8-K | $0.8210 | awaiting T+5 | — | $0.7208 (−12.20%) |
Oct 14, 2026 12d ago | SC 13G | $0.7808 $0.8400 | ▲ +7.58% | ▲ +7.13% | $0.7208 (−7.68%) |
Oct 13, 2026 13d ago | 8-K | $0.7818 $0.8210 | ▲ +5.01% | ▲ +6.17% | $0.7208 (−7.80%) |
Sep 14, 2026 5w ago | 8-K | $1.19 $1.33 | ▲ +11.76% | ▲ +9.64% | $0.7208 (−39.43%) |
Aug 28, 2026 8w ago | 8-K | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7208 (−47.00%) |
Aug 28, 2026 8w ago | Press Release | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7208 (−47.00%) |
Jul 1, 2026 16w ago | 8-K | $1.75 $1.59 | ▼ −9.14% | ▼ −9.40% | $0.7208 (−58.81%) |
May 15, 2026 23w ago | 3 | $1.47 $1.84 | ▲ +25.17% | ▲ +24.21% | $0.7208 (−50.97%) |
May 12, 2026 23w ago | Press Release | $1.55 $1.50 | ▲ +3.23% | ▲ +2.07% | $0.7208 (+53.50%) |
May 8, 2026 24w ago | 8-K | $1.66 $1.42 | ▼ −14.46% | ▼ −14.37% | $0.7208 (−56.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers